Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical (PROF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Profound Medical PROF shares soared 9.5% in the last trading session to close at $8.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement ...

Investors might want to bet on Profound Medical (PROF), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- With reference to its press release dated June 30, 2017, Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound”) announced today that all closing ...

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private ...